Anti-inflammatory therapeutics for the treatment of atherosclerosis

Nature Reviews Drug Discovery

Volumn 10, Issue 5, 2011, Pages 365-376

  Charo, Israel F ^a   Taub, Rebecca ^b  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATORVASTATIN; ATRELEUTON; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DARAPLADIB; EZETIMIBE; FLUORODEOXYGLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; MYELOPEROXIDASE; NICOTINIC ACID; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 INHIBITOR; STATIN; SUCCINOBUCOL; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARESPLADIB; VELIFLAPON;

ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; DRUG INHIBITION; DRUG RESEARCH; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION;

EID: 79955604190     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3444     Document Type: Review

References (86)

1. National Institutes of Health: National Heart, Lung and Blood Institute. 2009 NHLBI Morbidity and Mortality Chart Book. National Heart, Lung and Blood Institute [online], http://www.nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf (2009).
2. Ross, R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999). (Pubitemid 29054847)
3. Lusis, A. J. Atherosclerosis. Nature 407, 233-241 (2000).
4. Glass, C. K. & Witztum, J. L. Atherosclerosis: the road ahead. Cell 104, 503-516 (2001). (Pubitemid 32201946)
5. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002). (Pubitemid 36019640)
6. Libby, P., Ridker, P., Göran, K. & Hansson, K. Inflammation in atherosclerosis: from pathophysiology to practice. JACC Cardiovasc. Imaging 54, 2129-2138 (2009).
7. Dreschler, M., Megens, R., van Zandvoort, M., Weber, C. & Soehnlein, O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 122, 1837-1845 (2010).
8. Klingenberg, R. & Hansson, G. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 30, 2838-2844 (2009).
9. Virmani, R., Kolodgie, F., Burke, A., Farb, A. & Schwartz, S. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275 (2000). (Pubitemid 30262927)
10. O'Connor, R. et al. Part 9: acute coronary syndromes: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Circulation 122 (Suppl. 2), 422-465 (2010).
11. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004). (Pubitemid 38477774)
12. Mehta, S. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001). (Pubitemid 32772726)
13. Tardif, J.-C., Heinonen, T., Orloff, D. & Libby, P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 113, 2936-2942 (2006). (Pubitemid 44297235)
14. Nissen, S. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217-2225 (2004).
15. Barter, P. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007). (Pubitemid 350146106)
16. Kastelein, J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008). (Pubitemid 351482735)
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
18. Reifenberg, K. et al. Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler. Thromb. Vasc. Biol. 25, 1641-1646 (2005). (Pubitemid 41098934)
19. Ridker, P. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005). (Pubitemid 40075677)
20. Nissen, S. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005). (Pubitemid 40075678)
21. Zacho, J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908 (2008).
22. Ridker, P. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
23. Schindhelm, R., vanDerZwan, L., Teerlink, T. & Scheffer, P. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin. Chem. 55, 1462-1470 (2009).
24. Blankenberg, S. et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121, 2388-2397 (2010).
25. Möckel, M. et al. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin. Chem. 51, 1624-1631 (2005). (Pubitemid 41233097)
26. Wu, A. The role of cardiac troponin in the recent redefinition of acute myocardial infarction. Clin. Lab. Sci. 17, 50-52 (2004).
27. Fayad, Z. Cardiovascular molecular imaging. Arterioscler. Thromb. Vasc. Biol. 29, 981-981 (2009).
28. Tall, A., Yvan-Charvet, L., Terasaka, N., Pagler, T. & Wang, N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell. Metab. 7, 365-375 (2008). (Pubitemid 351598023)
29. Yvant-Charvet, L. et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30, 1430-1438 (2010).
30. Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. & Braunwald, E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100, 230-235 (1999). (Pubitemid 29340127)
31. Ridker, P. M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965 (2001). (Pubitemid 32568149)
32. Tsou, C. L. et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117, 902-909 (2007).
33. Yu, X. et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc. Natl Acad. Sci. USA 89, 6953-6957 (1992).
34. Swirski, F. K. et al. Ly-6Chi monocytes dominate hypercholesterolemia- associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117, 195-205 (2007). (Pubitemid 46048466)
35. Zapolska-Downar, D., Siennicka, A., Kaczmarczyk, M., Kołodziej, B. & Naruszewicz, M. Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells. Life Sci. 75, 1287-1302 (2004). (Pubitemid 38845028)
36. Aikawa, M. et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103, 276-283 (2001). (Pubitemid 32095415)
37. Steffens, S. & Mach, F. Anti-inflammatory properties of statins. Semin. Vasc. Med. 4, 417-422 (2004). (Pubitemid 40577831)
38. Schönbeck, U. & Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109, II18-26 (2004). (Pubitemid 38724152)
39. Zhou, Q. & Liao, J. Pleiotropic effects of statins - basic research and clinical perspectives. Circ. J. 74, 818-826 (2010).
40. Tardif, J. et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371, 1761-1768 (2008). (Pubitemid 351697951)
41. Solinas, G. et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell. Metab. 6, 386-397 (2007). (Pubitemid 350012000)
42. Rosenson, R. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 23, 93-101 (2009).
43. Suckling, K. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis 212, 357-366 (2010).
44. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375, 1536-1544 (2010).
45. Wilensky, R. et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nature Med. 10, 1059-1066 (2008).
46. Serruys, P. et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172-1182 (2008).
47. Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. The synergistic inhibition of atherogenesis in apoE- /- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623-629 (2009).
48. Hartford, M. et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int. J. Cardiol. 108, 55-62 (2006). (Pubitemid 43324907)
49. Rosenson, R., Elliott, M., Stasiv, Y., Hislop, C. & for the PLASMA II Investigators. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur. Heart J. 16 Nov 2010 (doi:10.1093/eurheartj/ehq374).
50. Peters-Golden, M. & Henderson, W. R. Jr. Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007).
51. DeCaterina, R. & Zampolli, A. From asthma to atherosclerosis-5- lipoxygenase, leukotrienes, and inflammation. N. Engl. J. Med. 350, 4-7 (2004).
52. Bäck, M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 23, 41-48 (2009).
53. Lötzer, K., Funk, C. & Habenicht, A. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim. Biophys. Acta 1736, 30-37 (2005). (Pubitemid 41208257)
54. Funk, C. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nature Rev. Drug Discov. 4, 664-672 (2005). (Pubitemid 41149760)
55. Mehrabian, M. & Allayee, H. 5-lipoxygenase and atherosclerosis. Curr. Opin. Lipidol. 14, 447-457 (2003). (Pubitemid 37297299)
56. Dwyer, J. et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. 350, 29-37 (2004). (Pubitemid 38032181)
57. Zhao, L. et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med. 10, 966-973 (2004). (Pubitemid 39273738)
58. Tabibiazar, R. et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol. Genomics. 22, 213-226 (2005). (Pubitemid 41356355)
59. Spanbroek, R. et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238-1243 (2003). (Pubitemid 36183986)
60. Cipollone, F. et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 25, 1665-1670 (2005). (Pubitemid 41098938)
61. Helgadottir, A. et al. Association between the gene encoding 5 lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. 76, 505-509 (2005). (Pubitemid 40250529)
62. Helgadottir, A. et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genet. 36, 233-239 (2004). (Pubitemid 38282747)
63. Assimes, T. et al. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum. Genet. 4, 399-408 (2008).
64. Hakonarson, H. et al. Effects of a 5 lipoxygenase activating protein inhibitor on biomarkers associated with risk of myocardial infarction. JAMA 293, 2245-2256 (2005). (Pubitemid 40629191)
65. Drazen, J. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999). (Pubitemid 29264811)
66. Tardiff, J.-C. et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 3, 298-307 (2010).
67. Nelken, N. A., Coughlin, S. R., Gordon, D. & Wilcox, J. N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 88, 1121-1127 (1991).
68. Cushing, S. D. et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl Acad. Sci. USA 87, 5134-5138 (1990).
69. Charo, I. F. et al. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl Acad. Sci. USA 91, 2752-2756 (1994). (Pubitemid 24139426)
70. Boring, L., Gosling, J., Cleary, M. & Charo, I. F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998). (Pubitemid 28410911)
71. Zernecke, A., Shagdarsuren, E. & Weber, C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28, 1897-1908 (2008).
72. Barlic, J., Zhang, Y., Foley, J. F. & Murphy, P. M. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation 114, 807-819 (2006). (Pubitemid 44268231)
73. Gilbert, J. et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum c-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 15 March 2011 (doi:10.10.1016/j.amjcard.2010. 11.005).
74. Aiello, R. et al. CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE-/- mice. Atherosclerosis 208, 370-375 (2010).
75. Piccinini, A. et al. Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J. Biol. Chem. 285, 8782-8792 (2010).
76. Koenen, R. R. et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nature Med. 15, 97-103 (2009).
77. Serbina, N. & Pamer, E. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nature Immunol. 7, 311-317 (2006).
78. Saag, K. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762-784 (2008). (Pubitemid 351847559)
79. Popa, C. et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64, 303-305 (2005). (Pubitemid 40193632)
80. Jacobsson, L. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 34, 1213-1218 (2005). (Pubitemid 40995372)
81. Ridker, P. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7 (Suppl.1), 332-339 (2009).
82. Fearon, W. & Fearon, D. Inflammation and cardiovascular disease; role of the interleukin-1 receptor antagonist. Circulation. 117, 2577-2579 (2008).
83. Haverslag, R., Pasterkamp, G. & Hoefer, I. Targeting adhesion molecules in cardiovascular disorders. Cardiovasc. Hematol. Disord. Drug Targets 8, 252-260 (2008).
84. Lindå, H. et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N. Engl. J. Med. 361, 1081-1087 (2009).
85. Crossman, D. et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART Study). Trials 25, 8 (2008).
86. White, H. et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Athersclerotic plaque By Initiation of darapLadIb TherapY comparing darapladib versus placebo in patients with coronary heart disease. Am. Heart J. 160, 655-661 (2010).